Literature DB >> 29287249

Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors.

Maria Laura Pati1, Mauro Niso2, Dirk Spitzer3, Francesco Berardi2, Marialessandra Contino2, Chiara Riganti4, William G Hawkins3, Carmen Abate5.   

Abstract

The aggressiveness of pancreatic cancer urgently requires more efficient treatment options. Because the sigma-2 (σ2) receptor was recently proposed as a promising target for pancreatic cancer therapy, we explored our previously developed multifunctional thiosemicarbazones, designed to synergistically impair cell energy levels, by targeting σ2 and P-gp proteins and chelating Iron. A deconstruction approach was herein applied by removing one function at a time from the potent multifunctional thiosemicarbazones 1 and 2, to investigate the contribution to cytotoxicity of each target involved. The results from in vitro (panel of pancreatic tumor cells) and in vivo experiments (C57BL/6 bearing KP02 tumor), suggest that while the multifunctional activity was not required for the antitumor activity of these thiosemicarbazones, σ2-targeting appeared to allow alternative tumor cell death mechanisms, leading to potent and less toxic off-targets toxicities compared to other thiosemicarbazones devoid of σ2-targeting.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Mithocondrial superoxide; Multifunctional compounds; Pancreatic cancer; Sigma-2 receptors; Thiosemicarbazones

Mesh:

Substances:

Year:  2017        PMID: 29287249      PMCID: PMC5801006          DOI: 10.1016/j.ejmech.2017.12.024

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  52 in total

1.  Development of sigma-1 (σ1) receptor fluorescent ligands as versatile tools to study σ1 receptors.

Authors:  Carmen Abate; Chiara Riganti; Maria Laura Pati; Dario Ghigo; Francesco Berardi; Timur Mavlyutov; Lian-Wang Guo; Arnold Ruoho
Journal:  Eur J Med Chem       Date:  2015-12-13       Impact factor: 6.514

2.  Novel and Selective Fluorescent σ2 -Receptor Ligand with a 3,4-Dihydroisoquinolin-1-one Scaffold: A Tool to Study σ2 Receptors in Living Cells.

Authors:  Mauro Niso; Chiara Riganti; Maria Laura Pati; Dario Ghigo; Francesco Berardi; Carmen Abate
Journal:  Chembiochem       Date:  2015-03-10       Impact factor: 3.164

3.  GRIND-derived pharmacophore model for a series of alpha-tropanyl derivative ligands of the sigma-2 receptor.

Authors:  Paola Cratteri; M Novella Romanelli; Gabriele Cruciani; Claudia Bonaccini; Fabrizio Melani
Journal:  J Comput Aided Mol Des       Date:  2004-05       Impact factor: 3.686

4.  Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy.

Authors:  Shakeel U R Mir; Steven R Schwarze; Ling Jin; Jinling Zhang; Woodrow Friend; Sumitra Miriyala; Daret St Clair; Rolf J Craven
Journal:  Autophagy       Date:  2013-09-04       Impact factor: 16.016

5.  Identification of the gene that codes for the σ2 receptor.

Authors:  Assaf Alon; Hayden R Schmidt; Michael D Wood; James J Sahn; Stephen F Martin; Andrew C Kruse
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

6.  Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines.

Authors:  Nicola Antonio Colabufo; Francesco Berardi; Marialessandra Contino; Mauro Niso; Carmen Abate; Roberto Perrone; Vincenzo Tortorella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-31       Impact factor: 3.000

7.  Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.

Authors:  Dannel Yeo; Nhi Huynh; John A Beutler; Christopher Christophi; Arthur Shulkes; Graham S Baldwin; Mehrdad Nikfarjam; Hong He
Journal:  Cancer Lett       Date:  2014-01-31       Impact factor: 8.679

8.  Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ₂ receptors.

Authors:  Carmen Abate; Svetlana V Selivanova; Adrienne Müller; Stefanie D Krämer; Roger Schibli; Roberta Marottoli; Roberto Perrone; Francesco Berardi; Mauro Niso; Simon M Ametamey
Journal:  Eur J Med Chem       Date:  2013-09-20       Impact factor: 6.514

9.  Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site.

Authors:  Jinbin Xu; Chenbo Zeng; Wenhua Chu; Fenghui Pan; Justin M Rothfuss; Fanjie Zhang; Zhude Tu; Dong Zhou; Dexing Zeng; Suwanna Vangveravong; Fabian Johnston; Dirk Spitzer; Katherine C Chang; Richard S Hotchkiss; William G Hawkins; Kenneth T Wheeler; Robert H Mach
Journal:  Nat Commun       Date:  2011-07-05       Impact factor: 14.919

10.  TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.

Authors:  Jia Cao; Jiachun Yang; Vijaya Ramachandran; Thiruvengadam Arumugam; Defeng Deng; Zhaoshen Li; Leiming Xu; Craig D Logsdon
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

View more
  7 in total

Review 1.  Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives.

Authors:  Francesca Serena Abatematteo; Mauro Niso; Marialessandra Contino; Marcello Leopoldo; Carmen Abate
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

2.  Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor.

Authors:  Chia-Chi Liu; Ching-Fang Yu; Shu-Chi Wang; Hsueh-Yin Li; Chiu-Min Lin; Hsia-Han Wang; Carmen Abate; Chi-Shiun Chiang
Journal:  BMC Cancer       Date:  2019-05-20       Impact factor: 4.430

Review 3.  PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships.

Authors:  Carmen Abate; Mauro Niso; Francesca Serena Abatematteo; Marialessandra Contino; Nicola Antonio Colabufo; Francesco Berardi
Journal:  Front Pharmacol       Date:  2020-12-07       Impact factor: 5.810

4.  New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4.

Authors:  Dario P Anobile; Mauro Niso; Adrian Puerta; Stephanie M Fraga Rodrigues; Francesca S Abatematteo; Amir Avan; Carmen Abate; Chiara Riganti; Elisa Giovannetti
Journal:  Molecules       Date:  2022-03-04       Impact factor: 4.411

5.  Novel Sigma-2 receptor ligand A011 overcomes MDR in adriamycin-resistant human breast cancer cells by modulating ABCB1 and ABCG2 transporter function.

Authors:  Zhanwei Zeng; Shiyi Liao; Huan Zhou; Hongyu Liu; Jiantao Lin; Yunsheng Huang; Chenhui Zhou; Daohua Xu
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

6.  MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor.

Authors:  Chiara Riganti; Roberta Giampietro; Joanna Kopecka; Costanzo Costamagna; Francesca Serena Abatematteo; Marialessandra Contino; Carmen Abate
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

Review 7.  Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease.

Authors:  Nicholas J Izzo; Martí Colom-Cadena; Aladdin A Riad; Jinbin Xu; Meharvan Singh; Carmen Abate; Michael A Cahill; Tara L Spires-Jones; Wayne D Bowen; Robert H Mach; Susan M Catalano
Journal:  eNeuro       Date:  2020-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.